I previously compared Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) (NONOF) in August 2025, discussing how the prior compounding/regulatory headwinds had triggered their painful corrections, worsened by Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects Summary Eli Lilly's GLP-1 portfolio outpaces Novo Nordisk's sluggish performance, supported by the former's superior tolerability, strategic distribution partnerships, expanding US market share, and accelerated revenue growth
Planning for a recurring expense Because GLP-1 therapy is ongoing, the useful question is not just this month's price but whether the monthly figure is stable enough to plan around
Formulated with clinically studied ingredients like Carniking (L-Carnitine), CoQ10, Taurine, and Hawthorn Berry, these chews work together to support heart function, energy levels, and healthy weight management
[DOI] [PubMed] [Google Scholar] 2.Wu G., Wu Z., Dai Z., et al